XBiotech Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $6.0 million for the three months ending September 30, compared to a loss of $5.0 million during the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $18.6 million, a decrease from the $28.0 million loss reported in the prior year. The company’s total operating expenses for the third quarter were $6.0 million, down from $7.9 million in the previous year, primarily due to reduced research and development costs, which fell to $5.1 million from $7.1 million.
The company’s cash and cash equivalents decreased to $147.4 million as of September 30, 2025, down from $183.1 million a year earlier. This decline is attributed to cash used in operating activities, which totaled $17.0 million for the nine months ended September 30, 2025, compared to $24.4 million in the same period of 2024. The decrease in cash used in operations was largely due to a reduction in clinical trial expenses, as no trials were active during the third quarter of 2025.
XBiotech has made strategic decisions to streamline its operations, including a significant reduction in research and development expenses, which accounted for 84% of total operating expenses in the third quarter of 2025, down from 90% in the same quarter of 2024. The company has also seen a decrease in its employee headcount, which stood at 88 as of September 30, 2025. The company continues to focus on its True Human™ monoclonal antibody pipeline, with no new product launches reported during this period.
Looking ahead, XBiotech anticipates continued operating losses as it advances its drug candidates through clinical trials. The company does not expect to generate revenue in 2025 and acknowledges the need for significant funding to support its ongoing research and development efforts. The management remains optimistic about the potential of its product candidates but recognizes the inherent risks and uncertainties associated with clinical development and market acceptance.
About XBiotech Inc.
XBiotech Inc. is a biopharmaceutical company specializing in discovering and developing True Human monoclonal antibodies from naturally immune donors. Its focus includes therapies targeting inflammatory and infectious diseases, notably IL-1a inhibitors for conditions like cancer, arthritis, and stroke. The company leverages proprietary manufacturing and clinical infrastructure, aiming to deliver safer, more effective biologics with potential for targeted, differentiated treatments across multiple medical indications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.